Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The first-in-human ENCIT01 trial comparing second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Tumor inflammation-associated neurotoxicity in children with diffuse intrinsic pontine glioma receiving B7-H3-targeting CAR T cells on BrainChild-03.

Neuro-oncology practice·2026

Same author

A pilot study of chemoimmunotherapy in the postconsolidation setting for high-risk neuroblastoma (ANBL19P1): A report from the Children's Oncology Group.

Cancer·2026

Same author

Adaptive Clinical Neuroblastoma Risk Groups-Tailoring Treatment in Low- and Middle-Income Countries: An International Neuroblastoma Risk Group Project.

JCO global oncology·2025

Same author

Sequential Combination of Unfavorable Histology, Followed by Clinical Stage M, Defines High-Risk Neuroblastoma: A Report from the Children's Oncology Group.

Clinical cancer research : an official journal of the American Association for Cancer Research·2025

Same author

Late effects after high-risk neuroblastoma (LEAHRN): a multicentre, cross-sectional cohort study from the Children's Oncology Group.

The Lancet. Child & adolescent health·2025

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

High-risk neuroblastoma: a therapy in evolution.

Abraham Fong¹, Julie R Park

¹Seattle Children's Hospital and University of Washington, Department of Pediatrics, Seattle, Washington 98105, USA.

Pediatric Hematology and Oncology

|December 4, 2009

Summary

High-risk neuroblastoma treatment faces challenges as conventional chemotherapy reaches its limit. Novel molecular- and immune-targeted therapies offer new hope by exploiting cancer cell biology.

Area of Science:

Pediatric Oncology
Cancer Therapeutics
Neuroblastoma Research

Background:

High-risk neuroblastoma presents a significant therapeutic challenge in pediatric oncology.
Conventional chemotherapeutics for neuroblastoma may have reached their maximum therapeutic efficacy.
There is a critical need for innovative treatment strategies beyond traditional chemotherapy.

Purpose of the Study:

To review current therapeutic approaches for high-risk neuroblastoma.
To highlight emerging novel treatment strategies targeting neuroblastoma biology.
To discuss the implications and future directions of these advanced therapies.

Main Methods:

Literature review of current and novel therapies for high-risk neuroblastoma.
Analysis of molecular- and immune-targeted agents.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: Jun 18, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Synthesis of information on therapeutic challenges and future research needs.

Main Results:

Conventional chemotherapy is nearing its therapeutic limit for high-risk neuroblastoma.
Novel therapies, including molecular- and immune-targeted agents, are being developed.
These agents aim to exploit specific neuroblastoma cell vulnerabilities.

Conclusions:

Novel therapeutic strategies are essential for improving outcomes in high-risk neuroblastoma.
These advanced treatments present new challenges and necessitate further investigation.
Continued patient enrollment in clinical trials is crucial for advancing neuroblastoma treatment.